[go: up one dir, main page]

BG104918A - Бензотиофени, бензофурани и индоли, полезни при лечение на резистентност към инсулин и хипергликемия - Google Patents

Бензотиофени, бензофурани и индоли, полезни при лечение на резистентност към инсулин и хипергликемия Download PDF

Info

Publication number
BG104918A
BG104918A BG104918A BG10491800A BG104918A BG 104918 A BG104918 A BG 104918A BG 104918 A BG104918 A BG 104918A BG 10491800 A BG10491800 A BG 10491800A BG 104918 A BG104918 A BG 104918A
Authority
BG
Bulgaria
Prior art keywords
carbon atoms
thiophen
bromo
dimethylnaphtho
alkyl
Prior art date
Application number
BG104918A
Other languages
Bulgarian (bg)
English (en)
Inventor
Jay Wrobel
Arlene Joan Dietrich
Madelene Miyoko Antane
Original Assignee
Wyeth
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wyeth filed Critical Wyeth
Publication of BG104918A publication Critical patent/BG104918A/bg

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D307/00Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/92Naphthofurans; Hydrogenated naphthofurans
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/48Drugs for disorders of the endocrine system of the pancreatic hormones
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D209/00Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/56Ring systems containing three or more rings
    • C07D209/58[b]- or [c]-condensed
    • C07D209/60Naphtho [b] pyrroles; Hydrogenated naphtho [b] pyrroles
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D333/00Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/50Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D333/74Naphthothiophenes

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Furan Compounds (AREA)
BG104918A 1998-05-12 2000-11-07 Бензотиофени, бензофурани и индоли, полезни при лечение на резистентност към инсулин и хипергликемия BG104918A (bg)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US7671298A 1998-05-12 1998-05-12
PCT/US1999/010209 WO1999061435A1 (en) 1998-05-12 1999-05-10 Benzothiophenes, benzofurans, and indoles useful in the treatment of insulin resistance and hyperglycemia

Publications (1)

Publication Number Publication Date
BG104918A true BG104918A (bg) 2001-08-31

Family

ID=22133746

Family Applications (1)

Application Number Title Priority Date Filing Date
BG104918A BG104918A (bg) 1998-05-12 2000-11-07 Бензотиофени, бензофурани и индоли, полезни при лечение на резистентност към инсулин и хипергликемия

Country Status (22)

Country Link
EP (1) EP1077969A1 (no)
JP (1) JP2002516321A (no)
KR (1) KR20010043539A (no)
CN (1) CN1308626A (no)
AR (1) AR015294A1 (no)
AU (1) AU756337B2 (no)
BG (1) BG104918A (no)
BR (1) BR9911779A (no)
CA (1) CA2330620A1 (no)
EA (1) EA200001175A1 (no)
EE (1) EE200000653A (no)
HR (1) HRP20000767A2 (no)
HU (1) HUP0101792A3 (no)
ID (1) ID26244A (no)
IL (1) IL139132A0 (no)
NO (1) NO20005677L (no)
PL (1) PL344081A1 (no)
SK (1) SK16992000A3 (no)
TR (1) TR200003333T2 (no)
TW (1) TW510900B (no)
WO (1) WO1999061435A1 (no)
ZA (1) ZA200005961B (no)

Families Citing this family (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6472545B2 (en) 2000-08-29 2002-10-29 Abbott Laboratories Protein tyrosine phosphatase inhibitors
WO2002018363A2 (en) * 2000-08-29 2002-03-07 Abbott Laboratories 3-phenyl-propanoic acid derivatives as protein tyrosine phosphatase inhibitors
AU2001292518A1 (en) * 2000-09-26 2002-04-08 Biovitrum Ab Novel compounds
US6498182B2 (en) 2000-09-26 2002-12-24 Biovitrum Ab Compounds
US6969730B2 (en) 2001-03-16 2005-11-29 Abbott Laboratories Amines as histamine-3 receptor ligands and their therapeutic applications
AR034375A1 (es) * 2001-06-07 2004-02-18 Wyeth Corp Combinacion de un inhibidor de ptpasa y un agente de sulfonilurea
US20030022896A1 (en) * 2001-06-07 2003-01-30 Wyeth PTPase inhibitors for improving cardiovascular risk profile
US20020198202A1 (en) * 2001-06-07 2002-12-26 Wyeth Combination of a PTPase inhibitor and an antilipemic agent
US6734197B2 (en) 2001-06-07 2004-05-11 Wyeth Combination therapy for type II diabetes or Syndrome X
WO2002098414A1 (en) * 2001-06-07 2002-12-12 Wyeth Methods using ptpase inhibitors and insulin
US20020198201A1 (en) * 2001-06-07 2002-12-26 Wyeth Combination of a PTPase inhibitor and an aldose reductase inhibitor
US20030055058A1 (en) * 2001-06-07 2003-03-20 Wyeth Combination of a PTPase inhibitor and an ACE inhibitor
US20030013709A1 (en) * 2001-06-07 2003-01-16 Wyeth Combination of a PTPase inhibitor and an alpha-glucosidase inhibitor
US20020198203A1 (en) * 2001-06-07 2002-12-26 Wyeth Combination of a PTPase inhibitor and a thiazolidinedione agent
TWI224101B (en) 2001-06-20 2004-11-21 Wyeth Corp Substituted naphthyl indole derivatives as inhibitors of plasminogen activator inhibitor type-1 (PAI-1)
DK1397130T3 (da) 2001-06-20 2007-11-12 Wyeth Corp Substituerede indolsyrederivater som inhibitorer af plasminogenaktivatorinhibitor-1 (PAI-1)
JP2005508355A (ja) * 2001-10-19 2005-03-31 トランス テック ファーマ,インコーポレイテッド 治療薬としてのビス−ヘテロアリールアルカン
US6984645B2 (en) 2001-11-16 2006-01-10 Bristol-Myers Squibb Company Dual inhibitors of adipocyte fatty acid binding protein and keratinocyte fatty acid binding protein
EP1452530A4 (en) 2001-12-03 2005-11-30 Japan Tobacco Inc AZOL CONNECTION AND THEIR MEDICAL USE
ITMI20022172A1 (it) * 2002-10-14 2004-04-15 Clariant Lsm Italia Spa Processo per la preparazione di 3-alchil-tiofeni-2, 5-disostituiti.
JP2006514637A (ja) 2002-12-10 2006-05-11 ワイス プラスミノーゲン活性化因子の阻害因子−1(pai−1)の阻害剤としての置換3−カルボニル−1h−インドール−1−イル酢酸誘導体
ATE430731T1 (de) 2002-12-10 2009-05-15 Wyeth Corp Substituierte indoloxoacetylaminoessigsäurederivate als inhibitoren des plasminogenaktivatorinhibitors-1 (pai-1)
UA80453C2 (en) 2002-12-10 2007-09-25 Derivatives of substituted dyhydropyranoindol-3,4-dion as inhibitors of plasminogen activator inhibitor-1 (pai-1)
DK1569899T3 (da) 2002-12-10 2006-10-23 Wyeth Corp Substituerede 3-alkyl- og 3-arylalkyl-1H-indol-1-yl-eddikesyrederivater som inhibitorer af plasminogenaktivator-inhibitor-1 (PAI-1)
DE60324183D1 (en) 2002-12-10 2008-11-27 Wyeth Corp Aryl-, aryloxy- und alkyloxysubstituierte 1h-indol-3-yl-glyoxylsäurederivateals inhibitoren des plasminogenaktivatorinhibitors-1 (pai-1)
WO2004106542A1 (ja) 2003-05-29 2004-12-09 Sankyo Company, Limited インスリン抵抗性改善剤及びそのスクリーニング方法
US7504401B2 (en) 2003-08-29 2009-03-17 Locus Pharmaceuticals, Inc. Anti-cancer agents and uses thereof
US7420083B2 (en) 2003-09-25 2008-09-02 Wyeth Substituted aryloximes
US7268159B2 (en) 2003-09-25 2007-09-11 Wyeth Substituted indoles
US7141592B2 (en) 2003-09-25 2006-11-28 Wyeth Substituted oxadiazolidinediones
US7534894B2 (en) 2003-09-25 2009-05-19 Wyeth Biphenyloxy-acids
US7371759B2 (en) 2003-09-25 2008-05-13 Bristol-Myers Squibb Company HMG-CoA reductase inhibitors and method
US7411083B2 (en) 2003-09-25 2008-08-12 Wyeth Substituted acetic acid derivatives
US7442805B2 (en) 2003-09-25 2008-10-28 Wyeth Substituted sulfonamide-indoles
US7163954B2 (en) 2003-09-25 2007-01-16 Wyeth Substituted naphthyl benzothiophene acids
US7265148B2 (en) 2003-09-25 2007-09-04 Wyeth Substituted pyrrole-indoles
US7351726B2 (en) 2003-09-25 2008-04-01 Wyeth Substituted oxadiazolidinediones
US7342039B2 (en) 2003-09-25 2008-03-11 Wyeth Substituted indole oximes
US7332521B2 (en) 2003-09-25 2008-02-19 Wyeth Substituted indoles
US7582773B2 (en) 2003-09-25 2009-09-01 Wyeth Substituted phenyl indoles
US7446201B2 (en) 2003-09-25 2008-11-04 Wyeth Substituted heteroaryl benzofuran acids
US7435837B2 (en) 2003-10-24 2008-10-14 Wyeth Dihydrobenzofuranyl alkanamine derivatives and methods for using same
FR2862645B1 (fr) * 2003-11-20 2007-06-22 Merck Sante Sas Composes antidiabetiques contenant des derives benzofuranes, benzothiophenes
US7420059B2 (en) 2003-11-20 2008-09-02 Bristol-Myers Squibb Company HMG-CoA reductase inhibitors and method
CN101044127A (zh) 2004-08-23 2007-09-26 惠氏公司 用作纤溶酶原激活剂抑制剂-1的噻唑基-萘基酸
US7186749B2 (en) 2004-08-23 2007-03-06 Wyeth Pyrrolo-naphthyl acids and methods for using them
BRPI0514544A (pt) 2004-08-23 2008-06-17 Wyeth Corp ácidos de oxazol-naftila como moduladores de inibidor tipo-1 de ativador de plasminogênio (pai-1)
WO2007022321A2 (en) 2005-08-17 2007-02-22 Wyeth Substituted indoles and use thereof
US8969514B2 (en) 2007-06-04 2015-03-03 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
WO2008151257A2 (en) 2007-06-04 2008-12-11 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
WO2009149279A2 (en) 2008-06-04 2009-12-10 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
CA2730603C (en) 2008-07-16 2019-09-24 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
GB0822486D0 (en) 2008-12-10 2009-01-14 Univ Liverpool Compounds for use in the treatment of pain
US9616097B2 (en) 2010-09-15 2017-04-11 Synergy Pharmaceuticals, Inc. Formulations of guanylate cyclase C agonists and methods of use
US9486433B2 (en) 2012-10-12 2016-11-08 Mochida Pharmaceuticals Co. Ltd. Compositions and methods for treating non-alcoholic steatohepatitis
WO2014142364A2 (en) 2013-03-15 2014-09-18 Mochida Pharmaceutical Co., Ltd. Compositions and methods for treating non-alcoholic steatohepatitis
EP2970384A1 (en) 2013-03-15 2016-01-20 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase and their uses
US10441560B2 (en) 2013-03-15 2019-10-15 Mochida Pharmaceutical Co., Ltd. Compositions and methods for treating non-alcoholic steatohepatitis
WO2014151200A2 (en) 2013-03-15 2014-09-25 Synergy Pharmaceuticals Inc. Compositions useful for the treatment of gastrointestinal disorders
AU2014274812B2 (en) 2013-06-05 2018-09-27 Bausch Health Ireland Limited Ultra-pure agonists of guanylate cyclase C, method of making and using same
CN106749169B (zh) * 2016-11-07 2020-04-21 浙江工业大学 一种Ertiprotafib的手性制备方法
CN107033122B (zh) * 2017-05-19 2019-06-14 南方医科大学 一种n-芳基-2-噻吩酰胺类衍生物及其制备方法和用途
JP7470342B2 (ja) 2018-04-26 2024-04-18 国立大学法人東京工業大学 多能性幹細胞の分化促進方法

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1242970A (en) * 1968-08-15 1971-08-18 Parke Davis & Co NEW BENZO[b]THIOPHENEACETIC ACID COMPOUNDS AND METHODS FOR THEIR PRODUCTION
US3639422A (en) * 1969-07-28 1972-02-01 Parke Davis & Co 4-phenylindole-1 (and 7)-acetic acids
US3682976A (en) * 1970-02-16 1972-08-08 Parke Davis & Co Phenyl benzofuran acetic acid compounds
GB8417559D0 (en) * 1984-07-10 1984-08-15 Pfizer Ltd Anti-diarrhoeal agents
FR2599740B1 (fr) * 1986-06-05 1988-08-12 Rhone Poulenc Sante Derives de benzo(b)thiophene de benzo(b)furannecarboxamides, leurs procedes de preparation et les medicaments les contenant
JPH01135766A (ja) * 1987-11-20 1989-05-29 Tanabe Seiyaku Co Ltd ビフェニル誘導体
US5110825A (en) * 1989-12-28 1992-05-05 Shionogi & Co., Ltd. Benzofuran derivative
US5340833A (en) * 1992-05-01 1994-08-23 Eisai Co., Ltd. Urokinase inhibitors
DE4425613A1 (de) * 1994-07-20 1996-01-25 Bayer Ag 5-gliedrige Heteroaryl-oxazolidinone

Also Published As

Publication number Publication date
ZA200005961B (en) 2001-10-24
CN1308626A (zh) 2001-08-15
BR9911779A (pt) 2001-02-06
CA2330620A1 (en) 1999-12-02
NO20005677L (no) 2000-12-05
AR015294A1 (es) 2001-04-18
IL139132A0 (en) 2001-11-25
AU3893999A (en) 1999-12-13
HRP20000767A2 (en) 2001-10-31
TW510900B (en) 2002-11-21
ID26244A (id) 2000-12-07
AU756337B2 (en) 2003-01-09
WO1999061435A1 (en) 1999-12-02
NO20005677D0 (no) 2000-11-10
KR20010043539A (ko) 2001-05-25
JP2002516321A (ja) 2002-06-04
HUP0101792A3 (en) 2003-01-28
SK16992000A3 (sk) 2001-04-09
HUP0101792A2 (hu) 2002-01-28
TR200003333T2 (tr) 2001-02-21
PL344081A1 (en) 2001-09-24
EP1077969A1 (en) 2001-02-28
EE200000653A (et) 2002-04-15
EA200001175A1 (ru) 2001-06-25

Similar Documents

Publication Publication Date Title
BG104918A (bg) Бензотиофени, бензофурани и индоли, полезни при лечение на резистентност към инсулин и хипергликемия
US6251936B1 (en) Benzothiophenes, benzofurans, and indoles useful in the treatment of insulin resistance and hyperglycemia
US6166069A (en) Phenyl oxo-acetic acids useful in the treatment of insulin resistance and hyperglycemia
CA2330623A1 (en) 11-aryl-benzo[b]naphtho[2,3-d]furans and 11-aryl-benzo[b]naphtho[2,3-d]thiophenes useful in the treatment of insulin resistance and hyperglycemia
JP4476624B2 (ja) プラスミノゲンアクチベーターインヒビター1(pai−1)のインヒビターとしてのナフチルベンゾフラン誘導体
EP1077965A1 (en) Phenyl oxo-acetic acids useful in the treatment of insulin resistance and hyperglycemia
EP1077967A2 (en) Biphenyl oxo-acetic acids useful in the treatment of insulin resistance and hyperglycemia
WO1999058522A1 (en) Naphtho[2,3-b]heteroar-4-yl derivatives
CA2538354A1 (en) Substituted naphthyl benzothiophene acids
US6110962A (en) 11-aryl-benzo[B]naphtho[2,3-D]furans and 11-aryl-benzo[B]naphtho[2,3-D]thiophenes useful in the treatment of insulin resistance and hyperglycemia
US6248764B1 (en) Furans, benzofurans, and thiophenes useful in the treatment of insulin resistance and hyperglycemia
US6057316A (en) 4-aryl-1-oxa-9-thia-cyclopenta[b]fluorenes
US6121271A (en) Naphtho[2,3-B]heteroar-4-yl derivatives
US6001867A (en) 1-aryl-dibenzothiophenes
US6340676B2 (en) 4-aryl-1-oxa-9-thia-cyclopenta (b) fluorenes
CZ20004182A3 (cs) Deriváty benzothiofenu, benzofuranu a indolu
JP2002514637A (ja) インスリン耐性および高血糖症の治療に有用なビフェニルスルホニルアリールカルボン酸
MXPA00011091A (en) Benzothiophenes, benzofurans, and indoles useful in the treatment of insulin resistance and hyperglycemia
MXPA00011089A (en) 11-aryl-benzo[b]naphtho[2,3-d]furans and 11-aryl-benzo[b]naphtho[2,3-d]thiophenes useful in the treatment of insulin resistance and hyperglycemia
MXPA00011086A (en) Biphenyl oxo-acetic acids useful in the treatment of insulin resistance and hyperglycemia